Low-dose megestrol enhances hormone therapy for ER-positive breast cancer, reducing tumor proliferation and improving ...

ER+/PR+ breast cancer is a subtype of ER positive breast cancer where the tumor cells express both estrogen receptors (ER) and progesterone receptors (PR) on the surface. As the most common type of ...

The presence of the progesterone receptor marks this tumor as hormone-responsive and indicates that hormone therapy should be considered as a component of her adjuvant therapy. In some breast cancer ...

Risk factors and predictors of tumor recurrence among breast cancer patients in a tertiary government hospital in the Philippines. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...

Epidemiologic risk factors associated with breast cancer subtypes. Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by ...

– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

October is Breast Cancer Awareness Month, which makes this a good time to learn about breast cancer types and what your type means. Breast cancer accounts for 1 in 3 of all new cancers diagnosed in ...

When you have breast cancer, your doctor may remove some or all of the cancer tissue through a biopsy or surgery. Then, they’ll order tests of these cells to help them learn more about the cancer. One ...

– evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of ...